Fast timing silicon R&D for the future Electron-Ion Collider
Explore the source record for details and available documents.
Xuan, Li↗
Engineering topics
Xuan, Li
Publications and source records attributed to Xuan, Li.
A demonstrator for a real-time AI-FPGA-based triggering system for sPHENIX at RHIC
The RHIC interaction rate at sPHENIX will reach around 3 MHz in pp collisions and requires the detector readout to reject events by a factor of over 200 to fit the DAQ bandwidth of 15 kHz. Some critical measurements, such as heavy flavor production in pp collisions, often require the analysis of particles produced at low momentum. This prohibits adopting the traditional approach, where data rates are reduced through triggering on rare high momentum probes. We explore a new approach based on real-time AI technology, adopt an FPGA-based implementation using a custom designed FELIX-712 board with the Xilinx Kintex Ultrascale FPGA, and deploy the system in the detector readout electronics loop for real-time trigger decision.
46 INSTRUMENTATION RELATED TO NUCLEAR SCIENCE AND ↗
A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia
Background Patients with refractory central nervous system leukemia (CNSL) have a dismal prognosis and lack effective therapy. Case reports have shown that sorafenib is effective against brain metastases, including leukemia. Methods To explore the efficacy of sorafenib combined with conventional therapies for refractory CNSL, a phase 2 study was conducted. The primary end point was the complete remission rate (CRR) within 8 weeks of treatment. Secondary end points included the overall response rate (ORR), event‐free survival (EFS), overall survival (OS), and adverse events (AEs). Results Twenty‐six patients with refractory CNSL were enrolled; they included 17 with isolated CNSL, 7 with hematological relapse, and 2 with another extramedullary relapse. After 8 weeks of treatment, 21 patients achieved complete remission, 2 achieved partial remission, and 3 achieved no remission for a CRR of 80.8% (95% CI, 62.1%‐91.5%) and an ORR of 88.5% (95% CI, 71.0%‐96.0%). Twenty patients survived, and 6 died. The 2‐year EFS and OS rates were 75.0% (95% CI, 54.5%‐88.3%) and 76.9% (95% CI, 54.2%‐90.4%), respectively. Six patients experienced grade 3 or 4 treatment‐related AEs, including moderate chronic graft‐vs‐host disease (n = 3), grade 3 or 4 acute graft‐vs‐host disease (n = 2), and grade 3 skin rash (n = 1). No treatment‐related deaths occurred during the therapy of refractory CNSL. Conclusions Sorafenib combined with conventional therapies is effective and safe for refractory CNSL. Lay Summary Sorafenib combined with conventional therapies is effective and safe for refractory central nervous system leukemia.
Chen, Xiaoxia↗